Dr. Conlin on theBenefits of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Alison K. Conlin, MD, medical oncology, Providence Cancer Institute Franz Clinic, discusses the benefits of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-low breast cancer. 

The phase 3 DESTINY-Breast04 trial (NCT03734029) evaluated the safety and efficacy of the antibody-drug conjugate (ADC) trastuzumab deruxtecan vs physician’s choice therapy as second-line therapy in patients with HER2-low breast cancer.

The results showed that the ADC should be used in the second-line setting, Conlin says. Although there are many treatments available, trastuzumab deruxtecan is a great option with a high rate of survival, Conlin explains.

Moreover, the duration of response is prolonged with the agent, Conlin continues. As such, this offers patients more time to receive subsequent therapies, Conlin concludes.